AXIN 10-K & 10-Q changes, risk factors and insider trading
Axiom Intelligence Acquisition Corp 1 (also AXINR, AXINU) · Nasdaq · Blank Checks · CIK 2057030 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Comparison not available: Not available: fewer than two 10-K filings on EDGAR to compare (only one so far)..
What changed in the latest 10-Q
Risk Factors
As a smaller reporting company under Rule 12b-2 of the Exchange Act, we are not required to include risk factors in this Report. However, for detailed descriptions of the risks relating to our Company, see the section titled “Risk Factors” contained in our (i) IPO Registration Statement, (ii) 2025 Q2 Quarterly Report, (iii) 2025 Annual Report and (iv) 2026 Q1 Quarterly Report. As of the date of this Report, there have been no material changes with respect to those risk factors. Any of these previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risks not presently known to us or that we currently deem immaterial may also affect our ability to consummate an initial Business Combination. We may disclose changes to such risk factors or disclose additional risk factors from time to time in our future filings with the SEC.
For the risks related to Terra Quantum and the Terra Quantum Business Combination, please see the registration statement on Form F-4 for the Terra Quantum Business Combination, once filed.
Removed heading “There is substantial doubt about our ability to continue as a “going concern.””
Largest changes
“There is substantial doubt about our ability to continue as a “going concern.””see in full comparison
“In connection with our assessment of going concern considerations under applicable accounting standards, Management has determined that our possible need for additional financing to enable us negotiate and complete our initial Business Combination, as well as the deadline by which we may be required to liquidate our Trust Account, raise substantial doubt about our ability to continue as a going concern through approximately one year from the date the unaudited condensed financial statements included in Item 1. “Financial Statements” of this Report were issued.”see in full comparison
“For the risks related to Terra Quantum and the Terra Quantum Business Combination, please see the registration statement on Form F-4 for the Terra Quantum Business Combination, once filed.”see in full comparison
Full comparison: every changed paragraph (4)
As a smaller reporting company under Rule 12b-2
of the Exchange Act, we are not required to include risk factors in this Report. However, for detailed descriptions of the risks relating
to our Company, see the section titled “Risk Factors” contained in our (i) IPO Registration Statement, (ii) 2025 Q2 Quarterly
Report, and (iii) 2025 Annual Report and (iv) 2026 Q1 Quarterly Report. As of the date of this Report, there have been no material changes with respect to those risk factors.
Any of these previously disclosed risk factors could result in a significant or material adverse effect on our results of operations or
financial condition. Additional risks not presently known to us or that we currently deem immaterial may also affect our ability to consummate
an initial Business Combination. We may disclose changes to such risk factors or disclose additional risk factors from time to time in
our future filings with the SEC.
For the risks related to Terra Quantum and the Terra Quantum Business Combination, please see the registration statement on Form F-4 for the Terra Quantum Business Combination, once filed.
There is substantial doubt about our ability
to continue as a “going concern.”
In connection with our assessment of going concern
considerations under applicable accounting standards, Management has determined that our possible need for additional financing to enable
us negotiate and complete our initial Business Combination, as well as the deadline by which we may be required to liquidate our Trust
Account, raise substantial doubt about our ability to continue as a going concern through approximately one year from the date the unaudited
condensed financial statements included in Item 1. “Financial Statements” of this Report were issued.
Management's Discussion & Analysis (MD&A)
New heading “Terra Quantum Business Combination”
New heading “Business Combination Agreement”
New heading “Representations and Warranties; Covenants”
New heading “Conditions to Each Party’s Obligations”
New heading “Survival; No Post-Closing Indemnification”
New heading “Sponsor Support Agreement”
New heading “Shareholder Voting, Support and Lock-Up Agreement”
Largest changes
“The Business Combination Agreement may be terminated under customary and limited circumstances prior to the Closing of the Terra Quantum Business Combination, including, but not limited to: (i) by mutual written consent of the Company and Terra Quantum; (ii) by the Company or Terra Quantum if any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any final and nonappealable Governmental Order making consummation of the Transactions illegal or otherwise preventing or prohibiting consummation of the Transactions; …”see in full comparison
“The obligations of the Company and Terra Quantum to consummate the Terra Quantum Business Combination are subject to certain closing conditions, including, but not limited to, (i) the Proxy/Registration Statement has become effective; (ii) the approval by the Company shareholders and the shareholders of Terra Quantum (or Swiss HoldCo shareholders, as applicable) of the transactions contemplated by the Business Combination Agreement and the other transaction proposals has been obtained; …”see in full comparison
“None of the parties nor any of their respective Affiliates, officers, directors, shareholders or Representatives shall have any liability following the Acquisition Closing for any breach of any representation, warranty, covenant or agreement contained in the Business Combination Agreement (other than covenants and agreements that by their terms expressly contemplate performance in whole or in part after the Acquisition Closing), and no claim may be brought by any Person against any party or any of their respective Affiliates, officers, directors, shareholders or Representatives with respect …”see in full comparison
“On May 25, 2026, the Company entered into the Business Combination Agreement with Terra Quantum, the Shareholder Representative, and, solely for purposes of Section 11.3 of the Business Combination Agreement, Ward. Pursuant to the terms of the Business Combination Agreement, the Sponsor will form PubCo, and PubCo will form Merger Sub. Following the formation of each Acquisition Entity, each such Acquisition Entity will enter into a joinder to the Business Combination Agreement, in form and substance satisfactory to the Company and Terra Quantum. …”see in full comparison
Full comparison: every changed paragraph (37)
All statements other than statements of historical
fact included in this Report including, without limitation, statements under this Item 2 regarding our financial position, possible Business
Combinations and the financing thereof, and related matters, and the plans and objectives of Management for future operations, are forward-looking
statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. When used in this Report, words
such as “may,” “should,” “could,” “would,” “anticipate,” “believe,”
“estimate,” “expect,” “intend” and similar expressions, as they relate to us or our Management, identify
forward-looking statements. We have based these forward-looking statements on our Management’s current expectations and projections
about future events, as well as assumptions made by, and information currently available to our Management. Actual results could differ
materially from those contemplated by thesuch forward-looking statements as a result of certain factors detailed in our filings with the SEC.
SEC, including herein. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety
by this paragraph.
Terra Quantum Business Combination
On May 25, 2026, the Company entered into the Business Combination Agreement with Terra Quantum, the Shareholder Representative, and, solely for purposes of Section 11.3 of the Business Combination Agreement, Ward. Pursuant to the terms of the Business Combination Agreement, the Sponsor will form PubCo, and PubCo will form Merger Sub. Following the formation of each Acquisition Entity, each such Acquisition Entity will enter into a joinder to the Business Combination Agreement, in form and substance satisfactory to the Company and Terra Quantum. The Business Combination Agreement and the transactions contemplated thereby were recommended by the special committee of the Board of Directors of the Company and were unanimously approved by the Board of Directors of each of the Company and Terra Quantum. Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Business Combination Agreement.
Business Combination Agreement
The Business Combination Agreement provides for, among other things, the following transactions: (i) prior to the Initial Closing, the shareholders of Terra Quantum will form Swiss HoldCo, and the shareholders of Terra Quantum will contribute their Company Shares into Swiss HoldCo such that Terra Quantum becomes a subsidiary of Swiss HoldCo; (ii) the Company will merge with and into Merger Sub, with Merger Sub as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly owned subsidiary of PubCo; and (iii) not earlier than one Business Day following the Initial Merger, Swiss HoldCo will merge with and into PubCo, with PubCo as the surviving entity in the merger. The Initial Merger, the Acquisition Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the “Terra Quantum Business Combination”. The Terra Quantum Business Combination is expected to close following the receipt of the required approval by the Company’s shareholders and the fulfillment of other customary closing conditions.
Representations and Warranties; Covenants
The Business Combination Agreement contains representations, warranties and covenants of each of the parties thereto that are customary for transactions of this type. The parties have also agreed, among other things, (i) that PubCo will adopt a new equity incentive plan establishing an initial share reserve equal to 10% of the outstanding PubCo Ordinary Shares on a fully diluted basis immediately following the Acquisition Closing (and including a 5% annual “evergreen” provision), and (ii) that on the Acquisition Closing, the Board of Directors of PubCo shall be reconstituted to consist of seven (7) directors, which shall include five (5) directors designated by Terra Quantum and two (2) directors designated by the Company. For U.S. federal income tax purposes, it is intended that the SPAC Reorganization will qualify as a “reorganization” under Section 368(a)(1)(F) of the Internal Revenue Code of 1986, as amended.
Conditions to Each Party’s Obligations
The obligations of the Company and Terra Quantum to consummate the Terra Quantum Business Combination are subject to certain closing conditions, including, but not limited to, (i) the Proxy/Registration Statement has become effective; (ii) the approval by the Company shareholders and the shareholders of Terra Quantum (or Swiss HoldCo shareholders, as applicable) of the transactions contemplated by the Business Combination Agreement and the other transaction proposals has been obtained; (iii) (a) PubCo’s listing application with Nasdaq is approved and (b) the PubCo Ordinary Shares to be issued in connection with the Terra Quantum Business Combination shall have been approved for listing on Nasdaq, subject to official notice of issuance; (iv) the accuracy of representations and warranties to various standards; (v) material compliance with pre-closing covenants; (vi)the establishment and securing of a combined company directors’ and officers’ liability insurance policy providing tail coverage for the Company; (vii) the bring-down to closing of a representation that no material adverse effect has occurred (both for the Company and Terra Quantum); (viii) the absence of a legal prohibition on consummating the transaction; (ix) compliance by Sponsor with certain provisions in the Sponsor Support Agreement (as defined below); (x) compliance by the shareholders of Terra Quantum with certain provisions in the Shareholder Support Agreements (as defined below); (xi) the delivery of customary certificates, ancillary agreements, and the Employment Agreements; and (xii) the receipt by the Company of a fairness opinion from an independent investment banking firm or other independent entity.
Termination
The Business Combination Agreement may be terminated under customary and limited circumstances prior to the Closing of the Terra Quantum Business Combination, including, but not limited to: (i) by mutual written consent of the Company and Terra Quantum; (ii) by the Company or Terra Quantum if any Governmental Authority shall have enacted, issued, promulgated, enforced or entered any final and nonappealable Governmental Order making consummation of the Transactions illegal or otherwise preventing or prohibiting consummation of the Transactions; (iii) by the Company or Terra Quantum if the Acquisition Closing shall not have occurred on the 30th Business Day following the occurrence of the Initial Closing; (iv) by Terra Quantum if the required vote at the Company Shareholders’ Meeting has not been obtained; (v) by Terra Quantum if the Company breaches certain provisions of the Business Combination Agreement; (vi) by the Company if there is any breach of any representation, warranty, covenant or agreement on the part of Terra Quantum or Swiss HoldCo such that the closing conditions would not be satisfied, subject to a 30-day cure period; and (vii) by Terra Quantum if there is any breach of any representation, warranty, covenant or agreement on the part of the Company or any Acquisition Entity such that the closing conditions would not be satisfied, subject to a 30-day cure period. In addition, the Business Combination Agreement may be terminated by either the Company or Terra Quantum if the transactions contemplated by the Business Combination Agreement have not been consummated on or prior to the date that is one (1) year after the initial filing date of the Proxy/Registration Statement with the SEC. The Business Combination Agreement also permits the Company to terminate the agreement during the Diligence Review Period if the Company determines, in its sole discretion, that the results of its continuing due diligence investigation of Terra Quantum, Swiss HoldCo or the Transactions are not satisfactory to the Company. In the event of such termination, Ward, the Company CEO, will be required to pay Terra Quantum a termination fee of $15,000,000 within five (5) Business Days following such termination.
Survival; No Post-Closing Indemnification
None of the parties nor any of their respective Affiliates, officers, directors, shareholders or Representatives shall have any liability following the Acquisition Closing for any breach of any representation, warranty, covenant or agreement contained in the Business Combination Agreement (other than covenants and agreements that by their terms expressly contemplate performance in whole or in part after the Acquisition Closing), and no claim may be brought by any Person against any party or any of their respective Affiliates, officers, directors, shareholders or Representatives with respect thereto.
The Business Combination Agreement contains representations, warranties, covenants and other agreements that the respective parties made to each other as of the date of such agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating the Business Combination Agreement.
Sponsor Support Agreement
Concurrently with the execution of the Business Combination Agreement, the Company, Terra Quantum and Sponsor entered into the Sponsor Support Agreement, pursuant to which Sponsor has agreed, among other things: (a) to vote all of its SPAC Shares in favor of the transactions contemplated by the Business Combination Agreement and other transaction proposals; (b) to vote against any proposals that would materially impede the transactions contemplated by the Business Combination Agreement or any other transaction proposal; (c) not to redeem any of its SPAC Shares in connection with SPAC Share Redemptions; (d) not to Transfer any of its SPAC Shares prior to the Acquisition Closing; and (e) not to Transfer any PubCo Ordinary Shares received in connection with the Initial Merger until the earlier of (i) 180 days after the Acquisition Closing Date, or earlier if, subsequent to the Acquisition Closing Date, the VWAP of the PubCo Ordinary Shares equals or exceeds $12.00 per share for any 20 trading days within any 30-trading day period commencing after the Acquisition Closing Date, or (ii) subsequent to the Acquisition Closing Date, the date on which PubCo consummates a liquidation, merger, share exchange or other similar transaction which results in all of PubCo’s shareholders having the right to exchange their PubCo Ordinary Shares for cash, securities or other property, in each case subject to certain permitted transfers.
Shareholder Voting, Support and Lock-Up Agreement
Concurrently with the execution of the Business Combination Agreement, the Company and Terra Quantum entered into a form of the Shareholder Support Agreement, to be entered into by certain shareholders of Terra Quantum, pursuant to which such shareholders will agree, among other things: (a) to vote all of their Company Shares (or, following the Swiss HoldCo Contribution, their Swiss HoldCo Shares) in favor of the Acquisition Merger and the other transactions contemplated by the Business Combination Agreement; (b) to vote against any proposals that would materially impede the transactions contemplated by the Business Combination Agreement; (c) to participate in the Swiss HoldCo Contribution; (d) to waive any dissenters’ rights and pre-emptive rights in connection with the transactions; (e) not to Transfer any of their Subject Shares prior to the Acquisition Closing; and (f) not to Transfer any PubCo Ordinary Shares received as Shareholder Merger Consideration until the earlier of (i) 180 days after the Acquisition Closing Date, or earlier if, subsequent to the Acquisition Closing Date, the VWAP of the PubCo Ordinary Shares equals or exceeds $12.00 per share for any 20 trading days within any 30-trading day period commencing after the Acquisition Closing Date, or (ii) subsequent to the Acquisition Closing Date, the date on which Terra Quantum consummates a subsequent liquidation, merger, share exchange or other similar transaction which results in all of Terra Quantum’s shareholders having the right to exchange their PubCo Ordinary Shares for cash, securities or other property, in each case subject to certain permitted transfers.
We have neither engaged in any operations nor
generated any revenues to date. Our only activities since January 30, 2025 (inception) through MarchJune 31,30, 2026 have been (i) organizational
activities and (ii) activities relating to (x) the Initial Public Offering and (y) identifying and evaluating prospective acquisition
candidates and activities in connection with the initial Business Combination. We will not generate any operating revenues until after
completion of our initial Business Combination. We have generated non-operating income in the form of interest income on investments held
in the Trust Account after the Initial Public Offering. We expect to incur increased expenses as a result of being a public company (for
legal, financial reporting, accounting and auditing compliance, among other things), as well as for due diligence expenses.
For the three months ended MarchJune 31,30, 2026, we
had net income of $1,520,809$747,721 which consists of interest earned on investments held in the Trust Account of $1,795,775,$1,838,193, offset by general
and administrative expenses of $274,966.$1,090,472.
For the periodthree frommonths Januaryended June 30, 2025 (inception)
through March 31, 2025, we had a net lossincome of $84,438,$74,168 which consists of interest earned on investments held in the Trust Account of $181,454, offset by general and administrative expenses.expenses of $107,286.
For the six months ended June 30, 2026, we had net income of $2,268,530 which consists of interest earned on investments held in the Trust Account of $3,633,968, offset by general and administrative expenses of $1,365,438.
For the period from January 30, 2025 (inception) through June 30, 2025, we had a net loss of $10,270 which consists of general and administrative expenses of $191,724, offset by interest earned on investments held in the Trust Account of $181,454.
Following the Initial Public Offering, including
the partial exercise of the Over-Allotment Option and the Private Placement, a total of $200,000,000 was initially placed in the Trust
Account. We incurred fees of $12,624,206, consisting of $4,000,000 of cash underwriting fee,fees, the Deferred Fee of $8,000,000, and $624,206
of other offering costs.
For the threesix months ended MarchJune 31,30, 2026, net
cash used in operating activities was $191,134.$446,739. Net income of $1,520,809$2,268,530 was affected by interest earned on investments held in the Trust
Account of $1,795,775.$3,633,968. Changes in operating assets and liabilities provided $83,832$918,619 of cash for operating activities.
For the period from January 30, 2025 (inception)
through MarchJune 31,30, 2025, net cash used in operating activities was $0. Net loss of $84,438$10,270 was affected by interest earned on investments held in the Trust Account of $181,454, payment of general and administrative
expenses through the IPO Promissory Note of $79,438.$35,894, and payment of general and administrative expenses through advances from the Sponsor of $93,601. Changes in operating assets and liabilities provided $5,000$62,209 of cash for operating
activities.
As of MarchJune 31,30, 2026, we had investments held
in the Trust Account of $206,030,469$207,868,662 (including approximately $1,795,775$3,633,968 of interest earned for the threesix months ended MarchJune 31,30, 2026)
consisting of money market funds. We may withdraw interest from the Trust Account to pay taxes, if any. We intend to use substantially
all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes
payable), to complete our Business Combination. To the extent that our share capital or debt is used, in whole or in part, as consideration
to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the
operations of the target business or businesses, make other acquisitions and pursue our growth strategies.
To mitigate the risk that we might be deemed to
be an investment company for purposes of the Investment Company Act, which risk increases the longer that we hold investments in the Trust
Account, we may, at any time, (based on our Management Team’s ongoing assessment of all factors related to our potential status
under the Investment Company Act) instruct the trusteeContinental to liquidate the investments held in the Trust Account and instead to hold the
funds in the Trust Account in cash or in an interest-bearing demand deposit account at a bank.
As of MarchJune 31,30, 2026, we had cash held outside
of the Trust Account of $545,146$289,541 and a working capital deficit of $518,422.$549,718. We use the funds held outside the Trust Account primarily to identify
and evaluate target businesses, perform business due diligence on prospective target businesses, travel to and from the offices, plants,
or similar locations of prospective target businesses or their representatives or owners, review corporate documents and material agreements
of prospective target businesses, and structure, negotiate and complete a Business Combination.
In order to fund working capital deficiencies
or finance transaction costs in connection with a Business Combination, the Sponsor, or certain of our officers and directors or their
affiliates may, but are not obligated to, loan us Working Capital Loans as may be required. If we complete a Business Combination, we
intend to repay such Working Capital Loans. In the event that a Business Combination does not close, we may use a portion of the working
capital held outside the Trust Account to repay such Working Capital Loans, but no proceeds from our Trust Account wouldwill be used for such
repayment. Up to $1,500,000 of such Working Capital Loans may be converted into units of the post-Business Combination entity at a price
of $10.00 per unit. TheSuch units (and underlying securities) would be identical to the Private Placement Units (and underlying securities).
Other than as set forth above, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist
with respect to such Working Capital Loans. As of MarchJune 31,30, 2026 and December 31, 2025, we did not have any borrowings under any Working
Capital Loans.
On July 27, 2026, the Sponsor agreed to loan the Company an aggregate of up to $1,000,000 pursuant to the Promissory Note. The Promissory Note was non-interest bearing, unsecured, shall be due and payable in cash on the earlier of (a) the date that the Company consummates the initial Business Combination, and (b) the date that the Company liquidates.
Notwithstanding anything contained in the Promissory Note to the contrary, at the Sponsor’s option, at any time prior to payment in full of the principal balance of the Promissory Note, the Sponsor may elect to convert all or any portion of the unpaid principal balance of the Promissory Note into number of Conversion Units, each Conversion Unit consisting of one Class A Ordinary Share of the Company and one Right to receive one-tenth (1/10) of a Class A Ordinary Share of the Company equal to: (x) the portion of the principal amount of the Promissory Note being converted, divided by (y) $10.00, rounded up to the nearest whole number of Units. Other than to the extent prohibited by the Company’s Amended and Restated Articles, the Conversion Units shall be identical to the Private Placement Units issued to the Sponsor in the Private Placement that simultaneously closed on the Company’s Initial Public Offering.
Commencing on June 17, 2025, and until the completion
of our Business Combination or liquidation, we may reimburse the Sponsor an aggregate of $10,000 per month for office space, utilities
and secretarial and administrative services pursuant to the Administrative Services Agreement. For the three and six months ended MarchJune 31,30, 2026
2026, the Company incurred and accrued an aggregate of $30,000 and $60,000, under the Administrative Services Agreement, respectively. For the three months ended June 30, 2025 and for the period from January 30, 2025 (inception) through MarchJune 31,30, 2025, wethe Company incurred an$497 aggregatein of $30,000 and $0fees for these services
under which were included in the Administrativeaccrued Servicesexpenses Agreement,in respectively.the accompanying balance sheets.
The preparation of the unaudited condensed financial
statements and notes thereto included in this Report under Item 1. “Financial Statements” in conformity with GAAP requires
Management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses, and the
disclosure of contingent assets and liabilities, in our unaudited condensed financial statements. These accounting estimates require the
use of assumptions about matters, some of which are highly uncertain at the time of estimation. Management bases its estimates on historical
experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis
for making judgments, and we evaluate these estimates on an ongoing basis. To the extent actual experience differs from the assumptions
used, our unaudited condensed financial statements and notes thereto included in this Report under Item 1. “Financial Statements”
could be materially affected. We believe that the following accounting policies involve a higher degree of judgment and complexity. Accordingly,
the actual results could materially differ from those estimates. As of MarchJune 31,30, 2026, we did not have any critical accounting estimates
to be disclosed.
We comply with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” We have two classes of Ordinary Shares, the (i) Class A Ordinary Shares and (ii) Company’s Class B Ordinary Shares, par value $0.0001 per share. Income and losses are shared pro rata between redeemable Class A Ordinary Shares and the sum of non-redeemable Class A and Class B Ordinary Shares. This presentation assumes a Business Combination as the most likely outcome. Net income (loss) per Ordinary Share is calculated by dividing net income (loss) by the weighted average number of Ordinary Shares outstanding for the respective periods.
We comply with the accounting and disclosure requirements
of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per Ordinary Share is computed by dividing net income (loss)
applicable to shareholders by the weighted average number of Ordinary Shares outstanding for the applicable periods. We apply the two-class
method in calculating earnings per Ordinary Share and allocate net income (loss) pro rata to Class A Ordinary Shares subject to possible
redemption, nonredeemable Class A Ordinary Shares and Class B Ordinary Shares. Accretion associated with the redeemable Class A Ordinary
Shares is excluded from earnings per share as the redemption value is not in excess of the fair value.
In November 2024, the FASB issued ASU 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures” (Subtopic 220-40), which requires public business entities to provide additional disclosures regarding certain expense captions presented on the face of the income statement. The standard requires qualitative and quantitative disclosure of specified expense categories included within relevant expense captions. The guidance is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statement disclosures.
AXIN insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding AXIN (13F)
| Investor | Quarter | Shares | Reported value | % of their 13F | Change vs prior quarter |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 968,981 | $10.0M | 0.01% | No change |
| Two Sigma Investments | 2026-06-30 | 634,375 | $6.6M | 0.0% | No change |
| Millennium Management (Israel Englander) | 2026-06-30 | 177,409 | $1.8M | 0.0% | Reduced 66% |
| Citadel Advisors (Ken Griffin) | 2026-06-30 | 30,914 | $317.8K | — | Sold out |
| Millennium Management (Israel Englander) | 2026-06-30 | 463,650 | $174.5K | 0.0% | Reduced 12% |